Amgen Inc(AMGN) shares were up 2.5% following the company’s announcement that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a randomized, double-blind, placebo-controlled 26-week long phase III study. The study evaluated the efficacy and safety of AMG 416 in 515 chronic kidney disease (CKD) patients receiving hemodialysis…
InterMune, Inc. (ITMN ) received breakthrough therapy designation for its primary product, Esbriet (pirfenidone), from the FDA. InterMune is looking to get Esbriet approved in the U.S. for the treatment of adults suffering from idiopathic pulmonary fibrosis (IPF). Breakthrough therapy designation is a status provided to candidates that show superiority over existing therapies for the…
AbbVie Inc and Shire have finally reached an agreement regarding the proposed acquisition of the latter by the former. As per the terms of the merger, AbbVie will pay approximately £53.19 per Shire share (£24.44 in cash and 0.8960 ordinary shares of the merged company for each Shire share). The deal is valued at £31.83…
It was all about AbbVie (ABBV) this past week in the biotech sector with the company finally succeeding in its efforts to make Shire (SHPG) agree to its acquisition proposal. Other news making it to the headlines include encouraging data from Amgen’s (AMGN) pipeline and breakthrough therapy status for InterMune’s (ITMN – Snapshot) lung disease…
In this Article, we take a close look at two upcoming Biotech stocks in Gilead & Anika. Biotechs Gilead Sciences (NASDAQ GILD) and Anika Therapeutics (NASDAQ ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared…
In the news on the Biotech Segment, we take a close look at three upcoming Biotech stocks in AbbVie, Bind Therapeutics & MannKind. Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders that a buyout is in their best interest. Per sources familiar with the dealings, AbbVie’s…
